Company intelligence
BBOT
Transforming the lives of patients with cancers driven by RAS and PI3Kα
Biotechnology Research
South San Francisco, US
96 employees
2 public signals
About BBOT
Best-in-RAS Transforming the lives of patients with cancers driven by RAS and PI3Kα
Verified activity
Signals from BBOT
2 published signals
Research & Knowledge
BBOT announced strategic prioritization of BBO-11818 and BBO-10203 combinations in KRAS-mutant cancers.
Reported by BBOT
Research & Knowledge
BBOT announced new clinical data for KRASG12C inhibitor BBO-8520 and strategic prioritization of BBO-8520 in combination with a checkpoint inhibitor in 2L+ KRASG12C inhibitor-experienced non-small cell lung cancer patients.
Reported by BBOT